arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Genprex, Inc.

GNPX
$3.72 ▲ +0.17 (+4.64%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
41 Visible periods
21 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Genprex, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.8M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -23.9%
FCF / Share $-10.86
Trailing P/E
Price / Book 0.1x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

41-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-4.46M
↓ -12.5%
FCF / Share Free cash flow per share
$-10.86
↓ -2305.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
2
Cash Quality
63

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 11 years · 41 quarters